XJTLU nanoparticle platform unifies exosome production
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Researchers at Xi'an Jiaotong-Liverpool University developed a nanoparticle-based manufacturing platform that integrates all four steps of engineered exosome production — release, drug loading, separation, and storage — for the first time, addressing a key bottleneck in scaling cell therapies.
- Dr. Gang Ruan of XJTLU's Wisdom Lake Academy of Pharmacy led the study, published in the journal Advanced Science, in which mesenchymal stem cells grown with specially designed nanoparticles release far more exosomes than usual and automatically pack in drugs and magnetic particles.
- The platform's "Russian doll" structure (drug-in-nanoparticle-in-exosome) allows extraordinarily high drug loading per exosome without damaging stability and enables imaging and tracking in biological environments.
- A new magnetic isolation technique called MIMS (mobile internal magnetic separation) collects exosomes quickly at large scales, unlike traditional methods that slow down as production increases, and the exosomes remain stable through freeze-drying and rehydration.
- The technology was validated in disease models including Parkinson's, pulmonary fibrosis, wound healing, heart failure, and polycystic ovary syndrome, with Dr. Ruan stating it could help patients gain faster access to safer, more effective therapies.
- Co-first author Dr. Xiaowei Wen of XJTLU's Jiangsu Province Higher Education Key Laboratory of Cell Therapy Nanoformulation said the system combined three new ideas: a new nanoparticle-cell interaction, a new nanomaterial type, and a new manufacturing equipment design.
Why it matters: Cell therapy developers gain an integrated pipeline for scaling engineered exosome production, with the technology validated across five disease models and Dr. Ruan stating it could help patients gain faster access to safer, more effective therapies.
